AREV Life Sciences Global Corp.

As of September 30, 2023, AREV Life Sciences Global Corp. has 31.76M shares outstanding.

These figures are as of September 30, 2023. The price-to-sales ratio is 396.35, and the price-to-book ratio stands at -2.46.

These figures are as of September 30, 2023. The EV/Sales ratio of 416.46 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of September 30, 2023, AREV Life Sciences Global Corp. maintains a current ratio of 0.05, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -12.51, indicating conservative leverage, while an interest coverage ratio of -35.16 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2023. Return on assets (ROA) is negative at -83.46, reflecting losses generated across the asset base. Return on capital employed (ROCE) is 296.71, useful for judging operating efficiency across full business cycles.

As of the close on July 11, 2023, AREV Life Sciences Global Corp.'s stock has declined approximately 18.18% over the past 52 weeks. The 50-day moving average sits at 0.14, while the 200-day moving average is 0.16.

Over the twelve months ended September 30, 2023, AREV Life Sciences Global Corp. posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -2,919.02 and net profit margin of -3,322.80 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2023. Free cash flow yield is negative at -5.26: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -4.90, meaning AREV Life Sciences Global Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

AREV Life Sciences Global Corp.'s most recent stock split took place on March 19, 2020 with a 6:1 split ratio.

As of September 30, 2023, AREV Life Sciences Global Corp. has an Altman Z-Score of -126.61, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.